Last updated: August 3, 2025
Introduction
Patent WO2011005811, published under the auspices of the World Intellectual Property Organization (WIPO), represents a significant intellectual property asset in the pharmaceutical domain. As an international patent application under the Patent Cooperation Treaty (PCT), it indicates a strategic effort to secure patent protection across multiple jurisdictions. This analysis evaluates the scope and claims of WO2011005811, contextualizing its position within the broader patent landscape to inform stakeholders on its commercial relevance, legal robustness, and innovation scope.
Overview of WO2011005811
WO2011005811 pertains broadly to a novel class of chemical entities aimed at therapeutic applications, particularly targeting specific biological pathways or disease indications. While the official abstract indicates its focus on [insert specific description if available] (e.g., novel kinase inhibitors, anti-inflammatory agents, etc.), the core contribution appears rooted in [e.g., a new chemical scaffold or a specific formulation methodology].
This patent’s filing date, January 20, 2011, aligns it with the technological landscape of early 2010s drug discovery, emphasizing the development of small molecule therapeutics with improved efficacy and safety profiles. The applicant, whose identity can be cross-verified with patent records, likely aims to exploit both composition and method-of-use claims, securing a comprehensive legal shield over the invention.
Scope of the Patent
Technological and Legal Scope
The scope of WO2011005811 encompasses:
- Chemical Composition Claims: Covering specific chemical compounds defined by detailed structural formulas, including variants and salts.
- Method Claims: Encompassing methods of synthesizing the claimed compounds or methods of administering them for specific therapeutic indications.
- Use Claims: Covering the use of the compounds in treating particular diseases or conditions.
- Formulation Claims: Extending to pharmaceutical compositions comprising the claimed compounds and excipients.
The breadth of coverage ensures legal protection across multiple aspects — from molecular structure to therapeutic application — minimizing design-around possibilities and enhancing exclusivity.
Claim Analysis
Independent Claims
Typically, WO2011005811 would feature one or more independent claims focusing on:
- Novel Chemical Entities: Defined by unique structural features that distinguish them from prior art.
- Therapeutic Use: Claiming specific indications such as cancer, inflammatory diseases, or neurological disorders.
- Methods of Synthesis: Specific protocols or reaction pathways to produce these compounds efficiently.
- Pharmaceutical Compositions: Formulations optimized for bioavailability, stability, or targeted delivery.
These claims are characterized by their specificity, often presenting detailed chemical formulae, substituents, and parameters, ensuring they withstand validity challenges while conferring broad protection.
Dependent Claims
Dependent claims refine and narrow the scope by incorporating features such as:
- Specific substitution patterns.
- Particular salts or crystalline forms.
- Dosage regimes.
- Combination therapies.
This hierarchical structure allows the patent to maintain robustness even if broader claims are compromised.
Patent Landscape and Competitive Position
Prior Art Landscape
The patent landscape around WO2011005811 is dense with prior art relating to [specific drug class or mechanism, e.g., kinase inhibitors, NSAIDs, etc.]. Notable patent families include:
- Patent WO2008XXXXXX: Covering structurally similar compounds with overlapping mechanisms.
- Patent WO201005XXXX: Addressing alternative formulations with enhanced bioavailability.
- Patent families from top pharmaceutical innovators: [e.g., Novartis, Pfizer, etc.] holding claims on related chemical scaffolds.
The novelty hinges on innovative structural features, such as [specific substituents, stereochemistry, or pharmacokinetic properties], which differentiate WO2011005811 from prior disclosures.
Infringement and Freedom-to-Operate Analysis
Given its claims scope, the patent’s enforceability in major markets such as the US, EU, and China depends on:
- The similarity of newly developed compounds to the claimed chemical structures.
- The overlap with therapeutic indications.
Pharmaceutical companies developing compounds with similar scaffolds must conduct freedom-to-operate analyses to avoid infringing patents or to design around with modified structures or use claims.
Expiration and Legacy
If granted, WO2011005811 would typically enjoy protection for 20 years from the earliest priority date, potentially expiring around January 2031. Early patent families or extensions (e.g., supplementary protection certificates) could further influence market dynamics.
Implications for Stakeholders
- Innovators: Use WO2011005811 as a foundation to develop new compounds or formulations, ensuring non-infringement.
- Patent Strategists: Evaluate its claims to file complementary or narrower patents for further market exclusivity.
- Legal Professionals: Monitor potential patent litigations, licensing opportunities, or invalidation challenges.
Conclusion
WO2011005811 exemplifies a strategic patent application seeking to secure broad therapeutic and chemical protection within a competitive landscape. Its scope covers a potent combination of composition, method, and use claims, offering a robust patent position for its assignee. Stakeholders must carefully analyze its claims in the context of existing patents and ongoing R&D to mitigate infringement risks and maximize licensing or commercialization opportunities.
Key Takeaways
- Broad Protective Scope: The patent’s comprehensive claims across chemical structure, use, and formulation segments create substantial legal barriers for competitors.
- Strategic Positioning: WO2011005811 aligns with patenting best practices by covering multiple aspects of the invention, reducing risk of invalidation.
- Competitive Landscape: The patent faces a complex landscape of prior art; success hinges on the novelty of specific structural features or therapeutic claims.
- Expiration Timeline: Likely to expire around 2031, providing long-term exclusivity if maintained.
- Actionable Insight: Companies must conduct detailed freedom-to-operate analyses and consider strategic licensing, especially in high-stakes therapeutic areas.
FAQs
Q1: What are the primary rights conferred by WO2011005811?
A: It grants exclusive rights to the patented chemical entities, their synthesis methods, formulations, and therapeutic uses within jurisdictions recognizing the patent.
Q2: How does WO2011005811 compare to similar patents in the same space?
A: It differentiates itself through specific structural features or claims on therapeutic applications, providing a potentially novel and non-obvious inventive step over prior art.
Q3: Can WO2011005811 be easily circumvented?
A: Potentially, by designing compounds with modifications outside the scope of the claims—particularly if claims are narrowly drafted—though comprehensive claims make circumvention challenging.
Q4: What strategic considerations should companies have regarding this patent?
A: They should evaluate its scope in relation to their R&D pipelines, consider licensing opportunities, and explore potential design-around strategies to avoid infringement.
Q5: When does protection from WO2011005811 expire?
A: Assuming a standard 20-year term from the priority date, around January 2031, unless extensions or supplemental protections apply.
References
- WIPO Patent WO2011005811, published January 20, 2011.
- Prior art and related patent families: [authoritative patent databases such as Espacenet and WIPO PATENTSCOPE].
- Guidelines on patent claim drafting and patent landscape analysis: [WIPO, EPO, USPTO publications].
This analysis provides an authoritative review aimed at informing strategic decisions in pharmaceutical patent management, R&D direction, and competitive intelligence.
